Aratana Therapeutics (PETX) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of Aratana Therapeutics (NASDAQ:PETX) from a hold rating to a sell rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “

Other equities research analysts also recently issued research reports about the company. TheStreet downgraded Aratana Therapeutics from a c- rating to a d+ rating in a research report on Monday, March 4th. William Blair downgraded Aratana Therapeutics from an outperform rating to a market perform rating and set a $4.14 target price on the stock. in a research report on Thursday, January 24th. Credit Suisse Group downgraded Aratana Therapeutics from an outperform rating to a neutral rating and set a $4.76 target price on the stock. in a research report on Tuesday, April 30th. Finally, HC Wainwright downgraded Aratana Therapeutics from a buy rating to a neutral rating and set a $5.00 target price on the stock. in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. Aratana Therapeutics presently has an average rating of Hold and an average price target of $5.08.

Aratana Therapeutics stock traded up $0.06 during trading on Wednesday, hitting $4.91. The stock had a trading volume of 99,619 shares, compared to its average volume of 916,000. Aratana Therapeutics has a 1 year low of $3.30 and a 1 year high of $7.16. The company has a market cap of $241.91 million, a price-to-earnings ratio of -15.34 and a beta of 1.49.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.04). The company had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $6.98 million. Aratana Therapeutics had a negative return on equity of 12.99% and a negative net margin of 33.47%. Equities analysts anticipate that Aratana Therapeutics will post -0.34 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Aratana Therapeutics by 2.7% during the third quarter. BlackRock Inc. now owns 3,439,584 shares of the biopharmaceutical company’s stock valued at $20,087,000 after purchasing an additional 91,344 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Aratana Therapeutics by 22.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,118,836 shares of the biopharmaceutical company’s stock worth $6,534,000 after acquiring an additional 208,508 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in shares of Aratana Therapeutics in the third quarter worth about $215,000. Vanguard Group Inc. increased its holdings in shares of Aratana Therapeutics by 3.8% in the third quarter. Vanguard Group Inc. now owns 2,044,208 shares of the biopharmaceutical company’s stock worth $11,938,000 after acquiring an additional 75,166 shares in the last quarter. Finally, Vanguard Group Inc increased its holdings in shares of Aratana Therapeutics by 3.8% in the third quarter. Vanguard Group Inc now owns 2,044,208 shares of the biopharmaceutical company’s stock worth $11,938,000 after acquiring an additional 75,166 shares in the last quarter. 66.83% of the stock is currently owned by hedge funds and other institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

Further Reading: What is the quiet period?

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.